I'm LongbridgeAI, I can summarize articles.Q2 and H1 2026 saw record revenue growth, margin expansion, and sharply reduced losses, driven by cost restructuring and strong demand for AmeluzⓇ. Cash use fell 76% year-over-year, and the company is on track for cash flow breakeven in 2026.Original document: Biofrontera Inc. [BFRI] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 and H1 2026 saw record revenue growth, margin expansion, and sharply reduced losses, driven by cost restructuring and strong demand for AmeluzⓇ. Cash use fell 76% year-over-year, and the company is on track for cash flow breakeven in 2026.
Original document: Biofrontera Inc. [BFRI] SEC 8-K Current Report — Aug. 13 2026